Analyst Pavan Patel from Bank of America Securities maintained a Buy rating on Supernus Pharmaceuticals and keeping the price target at $65.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pavan Patel has given his Buy rating due to a combination of factors highlighting Supernus Pharmaceuticals’ strategic progress and growth potential. The integration of Sage Therapeutics, which has surpassed expectations, is progressing smoothly with significant cost reductions and an anticipated $200 million in annual synergies. This showcases the company’s ability to effectively manage acquisitions and improve financial efficiency.
Another key driver behind the positive rating is the strong performance of Qelbree, Supernus’s ADHD treatment, which has shown significant growth in prescriptions, particularly among adults. Additionally, management’s proactive approach to addressing supply constraints for Onapgo, a Parkinson’s disease treatment, and their robust clinical pipeline, including developments in depression and epilepsy treatments, further supports the positive outlook for the company.